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21The pleiotropic activities of Interleukin (IL-)6 are controlled by membrane-bound and soluble forms of the
22IL-6 receptor (IL-6R) in processes called classic and trans-signaling, respectively. The coding single nucleo-
23tide polymorphism (SNP) rs2228145 of the Interleukin 6 receptor (IL-6R Asp358Ala variant) is associated
24with a 2-fold increase in soluble IL-6R (sIL-6R) serum levels resulting in reduced IL-6-induced C-reactive
25protein (CRP) production and a reduced risk for coronary heart disease. It was suggested that the increased
26sIL-6R level leads to decreased IL-6 classic or increased IL-6 trans-signaling. Irrespective of the functional
27outcome of increased sIL-6R serum level, it is still under debate, whether the increased sIL-6R serum levels
28emerged from differential splicing or ectodomain shedding. Here we show that increased proteolytic
29ectodomain shedding mediated by the A Disintegrin and metalloproteinase domain (ADAM) proteases
30ADAM10 and ADAM17 caused increased sIL-6R serum level in vitro as well as in healthy volunteers homo-
31zygous for the IL-6R Asp358Ala allele. Differential splicing of the IL-6R appears to have only a minor effect on
32sIL-6R level. Increased ectodomain shedding resulted in reduced cell-surface expression of the IL-6R Asp358Ala
33variant compared to the common IL-6R variant. In conclusion, increased IL-6R ectodomain shedding is a mech-
34anistic explanation for the increased serum IL-6R levels found in persons homozygous for the rs2228145 IL-6R
35 Asp358Ala variant.
36 © 2014 Published by Elsevier B.V.
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41 1. Introduction
42 Interleukin (IL-)6 plays an important role in health and disease [1,2].
43 The duration and strength of IL-6 cytokine-mediated signaling are
44 tightly regulated to avoid overshooting activities, e.g. acute-phase
45 response [3]. IL-6 activates signal transduction via homo-dimerization
46 of the ubiquitously expressed trans-membrane gp130 β-receptor,
47 which leads to subsequent activation of intracellular signaling pathways,
48 namely the Janus kinase/signal transducer and activator of transcription
49 (Jak/STAT), the phosphatidylinositide-3-kinase (PI3K) and the mitogen-
50 activated protein kinase (MAPK)-cascade pathway. To enable binding
51 to gp130, IL-6 needs an additional non-signaling IL-6 α-receptor
52 (IL-6R) [2,4], whose expression is restricted to hepatocytes and some
53 leukocyte populations. Consequently, IL-6 signaling is a priori limited
54to membrane-bound IL-6R expressing cells, in a process referred to as
55classic signaling [1,4].
56However, a soluble form of the IL-6R (sIL-6R) is found in many body
57ﬂuids. In concert with soluble gp130, also found in the serum, sIL-6R
58might act as an IL-6 buffer system, limiting overshooting systemic IL-6 ac-
59tions [5]. Paradoxically in trans-signaling, the sIL-6R in a complexwith IL-
606 is also able to induce signal transduction on cells which do not express
61IL-6R but only gp130 [3]. In recent years, trans- but not classic signaling
62was associated with chronic inﬂammatory diseases, such as rheumatoid
63arthritis and inﬂammatory bowel disease [3]. The sIL-6R is generated by
64two separate mechanisms: Limited proteolysis of the membrane-bound
65IL-6R precursor (also called ectodomain shedding) and differential splic-
66ing of the IL-6RmRNA. Ectodomain shedding of the IL-6R ismainlymedi-
67ated by A Disintegrin and Metalloproteinase domain (ADAM) proteases
68ADAM10 or ADAM17 [6,7]. Proteolytic cleavage of the IL-6R appears to
69be the predominant mechanism, as it is believed to account for 90% of
70the sIL-6R present in human serum.
71The IL-6R single nucleotide polymorphism (SNP) variant rs2228145 is
72associatedwith reduced C-reactive protein expression and a reduced risk
73to develop coronary heart disease [8,9]. The IL-6R variant rs2228145
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74 leads to an amino acid substitution of aspartic acid to alanine (Ala)
75 at amino-acid position 358 within the extracellular domain of the IL-6R
76 (Asp358Ala) and is strongly associatedwith a two-fold increase in sIL-6R
77 levels [10,11]. In Europe, the Asp358Alamutation is rather common, as it
78 has aminor allele frequency (MAF) of 30–40% [12]. This SNPwas recently
79 shown to result in increased generation of the differentially spliced solu-
80 ble IL-6R [13], reduced cell surface expression of IL-6R [14] and impaired
81IL-6 responsiveness of target cells indicating that the IL-6R Asp358Ala
82variant is biologically active [15]. The amino acid exchange is directly
83located within the ADAM17 cleavage site between Gln357 and Asp358
84of the common IL-6R variant (Ala358) [16], whereas the cleavage site
85for ADAM10was suggested to be located elsewhere [17]. It was hypothe-
86sized that the IL-6RAsp358Ala variant has a higher proteolytic conversion
87rate than the common IL-6R variant, concomitantly reducing IL-6
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Fig. 1. The coding single nucleotide polymorphism (SNP) rs2228145 (Asp358Ala) is associated with increased soluble IL-6R levels in humans. A. Schematic representation of the human
IL-6R consisting of an Ig-like domain (D1), the two domains containing the cytokine-binding module (CBM, D2 and D3), the stalk region, transmembrane and intracellular domain. The
ADAM17 cleavage site between Gln357 and Asp358 is indicatedwith a black triangle. B. Chromatograms showing the SNP rs2228145 (Asp358Ala) in exon 9 of IL6R. Upper panel shows a
wildtype situation (358Asp, A/A), whereas the lower panel shows a human homozygous for themutation (358Ala, C/C). C. Full bloodwas taken from ﬁve healthy donors homozygous for
the IL-6R SNP rs2228145 (referred to as C/C) and ﬁve healthy donors not carrying the SNP as controls (referred to as A/A) by venipuncture and serum isolated. Determination of sIL-6R
levels within the serum was performed with an ELISA speciﬁc for hIL-6R. D. Serum levels of sgp130 were determined in the serum samples described under C with an ELISA speciﬁc for
sgp130. E. Serum levels of IL-6 were determined in the serum samples described under C with an ELISA speciﬁc for human IL-6. F. PBMCs were isolated pair-wise from fresh blood of
humans with the A/A or C/C IL-6R genotype (see Materials and methods for details). Equal amounts of PBMCs were incubated for 2 h, and the amount of sIL-6R in the supernatant of
the PBMCswas quantiﬁedwith an ELISA speciﬁc for the IL-6R. The data shown in this graph are themean± S.D. of ﬁve independent experiments. G. The serum samples of the 10 healthy
donors described under panel Cwere analyzedwith an ELISA that speciﬁcally recognizes only the differentially spliced hIL-6R, but not the sIL-6R generated by limited proteolysis. Samples
below the detection limit (b31.25 pg/ml) are shown with a symbol directly on the x-axis. In graphs B, C, D and F, each symbol represents the mean of the ELISA measurement for the
individual participants. The horizontal lines indicate the mean of each group. P-values of the statistical analysis are given above the respective ﬁgure.
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88 signaling in target cells due to lower membrane-bound IL-6R expres-
89 sion [15]. Importantly, all previously published point mutations and
90 deletions surrounding the ADAM17-cleavage site in the IL-6R lead to
91 decreased proteolytic conversion rates [16,17].
92 Here, we show that Asp358Ala confers higher constitutive and
93 induced proteolytic conversion rates of the IL-6R mainly mediated by
94 ADAM10 and ADAM17.
95 2. Materials and methods
96 2.1. Cells and reagents
97 Ba/F3-gp130 cells were obtained from Immunex (now part of
98 Amgen Inc., Thousand Oaks, CA, USA [18]) and Ba/F3-gp130-hIL-6R
99 cells described previously [19]. HEK293 and HeLa cells were obtained
100 from DMSZ (Braunschweig, Germany). Murine embryonic ﬁbroblasts
101 deﬁcient for ADAM10, ADAM17, or both have been described previously
102 [20–22]. Parental Ba/F3-gp130 cells were cultured using 10 ng/ml re-
103 combinant hyper-IL-6 [23,24], and after transduction with the different
104 IL-6R constructs with 10 ng/ml recombinant human IL-6 [25]. PMA and
105 ionomycin were purchased from Sigma-Aldrich (Steinheim, Germany).
106 The anti-hIL-6R mAb tocilizumab (RoACTEMRA) was kindly provided
107 by Roche (Grenzach, Germany) and GI254023X and GW280264X by
108 Glaxo Smith Kline (Stevenage, UK) [26].
109 2.2. Construction of the hIL-6R plasmids
110 pcDNA3.1 containing human IL-6R was previously described [7].
111 The point mutation hIL-6R-Asp358Ala was introduced using standard
112 techniques.
113 2.3. Retroviral transduction and proliferation assays of Ba/F3-gp130 cells
114 All necessary IL-6R constructs were subcloned into the pMOWS vec-
115 tor. Ba/F3-gp130 cells were retrovirally transduced [27] and cytokine-
116 dependent proliferation was determined as described previously [28].
117 2.4. Flow cytometry
118 IL-6R cell surface expression on transiently transfected HEK293
119 cells was stained with 1:100 diluted anti-hIL-6R 4–11 mAb [19] and a
120 1:100 dilution of FITC-conjugated anti-mousemAb (Dianova, Hamburg,
121 Germany) in FACS buffer (0.5% BSA in PBS). Cells were analyzed on a BD
122 FACS Canto II (Becton-Dickinson, Heidelberg, Germany) as described
123 previously [17].
124 2.5. IL-6R protein turnover assay
125 Ba/F3-gp130-hIL-6R and Ba/F3-gp130-hIL-6R-Asp358Ala cells
126 were collected and pelletized at 5000 rpm for 1 min. Supernatants
127 were discarded, and cells were suspended at a concentration of
128 1 × 106 cells/ml in ice cold PBS. Cells were washed twice in ice cold
129 washing buffer (0.5% BSA/PBS) and pelletized (300 g, 4 °C, 5 min).
130 Cells were afterwards incubated with anti-hIL-6R antibody on ice for
131 1 h. To allow internalization, cells were washed 3 times with washing
132 buffer and incubated in DMEMwith 10% FBS at 37 °C for the times indi-
133 cated (0–120 min). After the incubation, cells were washed three times
134 with washing buffer at 4 °C and subsequently incubated at 4 °C for 1 h
135 with FITC-conjugated anti-mouse IgG. After additionalwashing, expres-
136 sion of receptors remaining at the cell surface was assayed as described
137 above.
138 2.6. Immunoﬂuorescence staining and confocal microscopy
139 HeLa cells were seeded onto glass coverslips in 6 well plates and
140 transiently transfected with either pcDNA3.1-hIL-6R or pcDNA3.1-hIL-
1416R_Asp358Ala using TurboFect (Thermo Scientiﬁc, St. Leon-Rot,
142Germany). To determine transfection efﬁciency, cells were transfected
143with a control plasmid containing GFP. GFP ﬂuorescencewas determined
144microscopically and was detectable in 60–70% of the cells. 48 h after
145transfection, cells were ﬁxed in 4% PFA for 20 min at room temperature.
146After washing with PBS, cells were blocked for 1 h in PBS with 1% BSA
147and 0.25% Triton X-100 for 1 h. Cells were stained with α-hIL-6R 4–11
148mAb (diluted 1:500 in 1% BSA/PBS) at 4 °C over night. Afterwards, cells
149were washed three times with PBS and stained with Alexa Fluor 546
150goat anti-mouse IgG (Invitrogen, Karlsruhe, Germany, diluted 1:500 in
1511% BSA/PBS) for 1 h at room temperature. Coverslips were washed
152three times with PBS afterwards and mounted with ProLong Gold
153Antifade reagent containing DAPI (Invitrogen, Karlsruhe, Germany)
154onto microscopy slides. Analyses were performed with a Leica TCS SP2/
155AOBSmicroscope equippedwith aHCXPLAPO63× immersion objective.
1562.7. Genotyping and isolation of human peripheral bloodmononuclear cells
157(PBMCs)
158Ethic approval for this study was obtained from the institutional re-
159view board of the Heinrich-Heine-University (study #3949). All partic-
160ipants gave written informed consent. Genomic DNA was isolated from
161buccal cells, part of the IL-6R ampliﬁed (5′: GAGGGGAAGGTTCCTTTG
162AG, 3′: CATGGCATGCTTTTTGTAGC) and genotype determined by
163sequencing. Afterwards, peripheral blood from healthy volunteers
164was collected by venipuncture. PBMCs were isolated using LSM 1077
165Lymphocyte Separation Medium (PAA Laboratories, Pasching, Austria)
166analogous as described previously [19].
1672.8. Shedding assays and ELISA
168Shedding assays were performed as previously described [7], and
169the data analysis and calculation was done according to Baran et al.
170[17]. An ELISA speciﬁc for all hIL-6R variants [7,19] as well as an ELISA
171speciﬁc for the differentially spliced shIL-6R (DS-sIL-6R)were described
172previously [29]. The gp130 ELISA was from R&D Systems (Wiesbaden,
173Germany), and the IL-6 ELISA was purchased from ImmunoTools
174(Friesoythe, Germany).
1752.9. Western blotting
176Transiently transfectedHEK293 andMEF cells were lysed inmild lysis
177buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, complete
178protease inhibitor mixture tablets), and 50 μg was loaded per lane onto
17910% SDS gels. Western blotting using anti-human IL-6R [4–11] and anti
180β-actin antibodies was performed as described previously [7,30].
1812.10. Statistical analysis
182Data are expressed as mean values ± standard deviation calculated
183from at least three independent experiments unless otherwise stated.
184Statistical analysis was performed using a one-tailed Mann–Whitney-
185U test. P-values are either given directly within the ﬁgures, or a P-value
186below 0.05 is indicated with an asterisk (*).
1873. Results
1883.1. Increased sIL-6R serum levels in homozygous carriers of the IL-6R SNP
189rs2228145 (Asp358Ala variant) were not caused by differential splicing of
190the IL-6R mRNA
191The soluble IL-6R serum level is derived from differential splicing
192or limited proteolysis of the membrane-bound IL-6R, and the latter is
193believed to account for at least 90–99% of the total sIL-6R found in
194human blood. ADAM10 and ADAM17 are themajor proteases responsi-
195ble for IL-6R shedding, and the cleavage site of ADAM17 within the
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196 juxtamembrane stalk region of the IL-6R has been determined to be lo-
197 cated between Gln357 and Asp358 ([31] and Fig. 1A). Interestingly, the
198 single nucleotide polymorphism (SNP) rs2228145 resulted in an amino
199acid substitution within the ADAM17 cleavage site, as aspartic acid 358
200is converted to an alanine (Asp358Ala, Fig. 1B). Cell surface expression
201of the IL-6R Asp358Ala variant is markedly reduced compared to the
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202 common IL-6 variant on naïve CD4+ T-cells, CD4+ memory T cells,
203 CD4+ regulatory T cells and monocytes, resulting in reduced IL-6 re-
204 sponsiveness of these cells [15]. Moreover, the IL-6R Asp358Ala variant
205 has been shown to be associated with increased sIL-6R level in the
206 serum of homozygous carriers [10,11]. To conﬁrm this ﬁnding, 37
207 healthy age-matched (25–35 years) volunteers were genotyped for
208the occurrence of the IL-6R SNP rs2228145 (15 A/A (wild-type, common
209allele), 16 A/C (heterozygous), 6 C/C (rs2228145)), and sera were drawn
210from ﬁve volunteers carrying the common IL-6R (A/A) allele and ﬁve
211homozygous carriers of rs2228145 (C/C). Indeed, homozygosity for
212the Asp358Ala mutation was associated with signiﬁcantly increased sIL-
2136R serum levels (A/A: 26.4 ± 4.8 ng/ml; C/C: 44.0 ± 5.1 ng/ml; p =
Fig. 2. The Asp358Ala IL-6R variant shows a reduced cell-surface expression and an increased protein turnover. A. HEK293 cells were transiently transfected with either IL-6R wildtype, IL-6R
Asp358Ala or left untransfected. Cell surface expression of the IL-6Rwas determined viaﬂowcytometry 48 h after transfection. B. The cells described under panel Awere lysed, and the amount
of IL-6Rwithin the lysate determined via ELISA andWestern blotting. One representative experiment of three performed is shown. n. s.: No signiﬁcant difference. C. HeLa cellswere transiently
transfectedwith either IL-6Rwildtype or IL-6RAsp358Ala. Cellswere grownon cover slips,ﬁxed and stained 48 h later. TheDAPI stainednucleus is shown in blue,whereas the IL-6R staining is
shown in red. Five different microscopic ﬁelds per IL-6R variant are shown. D. Equal amounts of Ba/F3-gp130-hIL-6R and Ba/F3-gp130-hIL-6R-Asp358Ala cells were stimulatedwith 10 ng/ml
hyper-IL-6, 10 ng/ml IL-6, 10 ng/ml IL-6 plus 100 μg/ml tocilizumab or left untreated. Cell viability was assessed 48 h later. One representative experiment of three performed is shown.
E. Equal amounts of Ba/F3-gp130-hIL-6R and Ba/F3-gp130-hIL-6R-Asp358Ala cells were stained with anti-IL-6R antibody, and the time-dependent protein turnover of the IL-6R (0–
120min) was determined as described in Experimental proceduresQ2 . Cells were pretreated for 30 min with the ADAM10/17metalloprotease inhibitor GWwhere indicated. As control, parental
Ba/F3-gp130 cells were stained with the anti-IL-6R antibody. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 3. Constitutive and stimulated shedding of the interleukin 6-receptor variant Asp358Ala is increased compared to the common IL-6R variant. A. HEK293 cells were transiently transfected
with expression plasmids coding for IL-6R wildtype and Asp358Ala. Cells were equally distributed one day later onto 6 well-plates, and stimulated 24 h later for 60 min with 1 μM ionomycin
(Iono) or treatedwithDMSO as negative control. The soluble IL-6R in the supernatantwas quantiﬁed via ELISA. The amount of solublewildtype IL-6Rwas set to 100%, and all other valueswere
calculated accordingly. ELISA results show themean±S.D. of three independent experiments. B. The experimentwas performed as described under panel A, except that cells were stimulated
with 100 nM PMA for 120 min. C. HEK293 cells were transiently transfected with expression plasmids coding for IL-6R wildtype and Asp358Ala. Cells were equally distributed one day later
onto 6 well-plates. The next day, medium was replaced and conditioned media collected at the time points indicated. The soluble IL-6R in the supernatant was quantiﬁed via ELISA. C. The
experimentdescribed under panel Cwas performedwithNIH3T3 cells. E. The experimentwas performedas describedunder panel A. Cellswere pretreated for 30minwith themetalloprotease
inhibitors GI (speciﬁc for ADAM10) or GW (speciﬁc for ADAM10 and ADAM17) where indicated. One representative experiment of three performed is shown. F. The experiment was
performed as described under panel C, except that cells were stimulated with 100 nM PMA for 120 min. One representative experiment is shown.
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214 0.004; Fig. 1C). Importantly, the rs2228145 SNP solely inﬂuenced
215 sIL-6R serum levels, since neither sgp130 (A/A: 170.9 ± 24.5 ng/ml;
216 C/C: 165.9 ± 21.9 ng/ml: p = 0.5; Fig. 1D) nor IL-6 (A/A: 17.8 ±
217 14.8 pg/ml; C/C: 19.2 ± 31.9 pg/ml; p = 0.21; Fig. 1E) showed any
218 statistical signiﬁcant difference between the two groups investigated.
219 Moreover, peripheral bloodmononuclear cells (PBMCs)were isolat-
220 ed from fresh blood samples of the ten volunteers, homozygous either
221 for the common or the IL-6R Asp358Ala allele. Blood was drawn on
222 ﬁve different days from age and sex-matched pairs (one genotype of
223 each on the same day), and cell culture supernatants were analyzed
224 for sIL-6R by ELISA. The data were analyzed pairwise on a daily basis,
225 to exclude qualitative differences between the preparations of the
226 cells on different days and subsequently summarized as x-fold increase
227 of sIL-6R using the sIL-6R levels from the daily prepared common IL-6R
228 variant as basis. As shown in Fig. 1F, conditioned cell culture superna-
229 tants of PBMCs homozygous for the Asp358Ala IL-6R variant contained
230 signiﬁcantly more sIL-6R (2.5 ± 1.1-fold, p = 0.025) compared to
231 homozygous carriers of the common IL-6R variant.
232Stephens et al. have previously shown that rs228145 increases
233the differential splicing of the IL-6R [13]. Therefore, we analyzed if the
234increased sIL-6R level were due to increased level of differentially
235spliced sIL-6R (DS-sIL-6R). An ELISA speciﬁcally detecting the alterna-
236tive C-terminus of DS-sIL-6R but not the proteolytically processed sIL-
2376R revealed that below1%of the sIL-6R is generated bydifferential splic-
238ing (Fig. 1G), which is consistent with other studies [32,33]. We can,
239however, not exclude that the new C-terminus of the differentially
240spliced sIL-6R variant is further processed after secretion, which might
241lead to underestimation of the differentially spliced sIL-6R variants.
242Four out of ﬁve serum samples from healthy volunteers, homozygous
243for the C allele in rs2228145, had detectable DS-sIL-6R levels, whereas
244in all other serum samples, DS-sIL-6R was below the detection limit
245(b31.25 pg/ml) of the ELISA.
246Even though our results conﬁrmed the earlier report that the
247C/C genotype conferred increased production of spliced sIL-6R
248as compared to the A/A variant [13], they suggested that ecto-
249domain shedding but not differential splicing mechanism mainly
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Fig. 4. Increased shedding of the Asp358Ala IL-6R variant in protease-deﬁcient murine embryonic ﬁbroblasts (MEFs). A. Wildtype, ADAM10−/−Q3 , ADAM17−/− and ADAM10−/−/17−/−
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250 contributes to the overall generation of the sIL-6R found in human
251 plasma.
252 3.2. The IL-6R Asp358Ala variant has an increased cell surface release rate
253 compared to the common IL-6R variant
254 Cell surface expression of the IL-6R Asp358Ala variant has been
255 shown to be reduced compared to the common IL-6R variant [14,15]
256 and human PBMCs release more sIL-6R (Fig. 1F), suggesting that
257 ectodomain shedding is the main driving force behind the increased
258 sIL-6R serum level. Interestingly, cell surface expression of the IL-6R
259 Asp358Ala variant in transiently transfected HEK293 cells was also
260 lower compared to the common IL-6R variant (Fig. 2A), even though
261 cellular IL-6R expression was comparable (Fig. 2B). Both IL-6R variants
262 were able to induce IL-6 dependent signaling in stable transduced
263 Ba/F3-gp130 cells, which could be blocked by themonoclonal antibody
264 tocilizumab (Fig. 2C). Using confocal microscopy, intense cell surface
265 staining for the common IL-6R variant was detected (Fig. 2D, top
266 panel), whereas the IL-6R Asp358Ala variant was only sparely detected
267 on the cell surface (Fig. 2D, lower panel). Taken together, ectopic
268 expression of the IL-6R Asp358Ala variant led to reduced cell-surface
269 expression compared to the common IL-6R variant, which resembles
270 the in vivo situation.
271 Next, we analyzed if an increased proteolytic turnover of the IL-6R
272 Asp358Ala variant contributes to the diminished amount of membrane-
273 bound IL-6R. Reduced overall cell surface expression of the Asp358Ala
274 IL-6R variant was also detected in Ba/F3-gp130-IL-6R cells (Fig. 2E). Cell
275 surface expressed IL-6R was labeled with hIL-6R antibodies on these
276 cells. Labeling was conducted at 4 °C and non-bound anti-IL-6R antibod-
277 ies were washed away. Cells were shifted back to 37 °C for 0, 30, 60, 90
278 and 120 min to allow IL-6R ectodomain shedding and internalization.
279 Thereafter, the cells were stained with secondary FITC-conjugated anti-
280 mouse IgG detection antibody at 4 °C to quantify the remaining cell
281 surface expressionof IL-6Rbyﬂowcytometry. During the pulse-chase ex-
282 periment, time-dependent reduction of the cell surface IL-6R expression
283 was faster for the IL-6R Asp358Ala variant compared to the common
284 IL-6R variant (Fig. 2E). To differentiate between ectodomain shedding
285 and receptor internalization, constitutive IL-6R shedding was blocked
286 by themetalloproteinase inhibitor GW280264X (GW), which is selective
287 for the main IL-6R sheddases ADAM10 and ADAM17. Inhibition of IL-6R
288 shedding had almost no effect on the cell surface expression of the
289 common IL-6R variant, suggesting that the reduction of IL-6R cell surface
290 expression was mainly caused by receptor internalization (Fig. 2E,
291 compare upper two panels). Interestingly, blockade of ADAM10 and
292 ADAM17 decelerated the cell surface down-regulation of the IL-6R
293 Asp358Ala variant almost to the rate observed for the common IL-6R var-
294 iant (Fig. 2E, compare lower two panels). Our data suggest that mainly
295 ectodomain shedding contributes to the accelerated IL-6R cell surface
296 down-regulation of the IL-6R Asp358Ala variant and directly cause the
297 increased sIL-6R levels.
298 3.3. The IL-6R Asp358Ala variant has an increased inducible proteolytic
299 conversion rate
300 Cellular stimulation with the calcium ionophor ionomycin or
301 the phorbolester PMA resulted in induced shedding of the IL-6R by
302 ADAM10 and ADAM17, respectively [7]. Therefore, we transiently
303 transfected HEK293 cells with cDNAs coding for either the common or
304 the Asp358Ala IL-6R variant and stimulated shedding with either
305 ionomycin or PMA.
306 We set the amount of sIL-6R after stimulation to 100% and calculated
307 all other values according to this, which allows the comparison of
308 the different IL-6R variants [17]. The amount of shed sIL-6R of the
309 Asp358Ala variant was slightly but signiﬁcantly increased compared to
310 the common IL-6R variant after ionomycin or PMA treatment (125 ±
311 2.4%, p b 0.05, Fig. 3A; 134.5 ± 13.7%, p b 0.05, Fig. 3B, respectively).
312Interestingly, also constitutively shed sIL-6R of the Asp358Ala IL-6R
313variant was increased in HEK293 cells compared to the common IL-6R
314variant (18.7 ± 5.2% vs. 27.7 ± 5.7%, p b 0.05, Fig. 3A; 17.2 ± 4.9% vs.
31525.3± 4.9%, p b 0.05, Fig. 3B). Time-course experiments with transiently
316transfected HEK293 (7 h) and NIH3T3 (4 h) conﬁrmed the increased
317constitutive proteolytic sIL-6R release of the Asp358Ala variant (Fig. 3C
318and D).
319To ensure that ionomycin and PMA selectively activated ADAM10
320and ADAM17, we used the protease inhibitors GI254023X (GI), which
321is selective for ADAM10, and GW280264X (GW), which is selective for
322both ADAM10 and ADAM17. Again, stimulation with ionomycin or
323PMA induced more IL-6R shedding for the Asp358Ala variant, which
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Fig. 5. Primary human peripheral blood mononuclear cells (PBMCs) from individuals ho-
mozygous for the rs2228145 (Asp358Ala) variant show higher ectodomain shedding of
the IL-6R. PBMCs were isolated pair-wise from fresh blood of humans with the A/A or
C/C IL-6R genotype (see Materials and methods for details). In all experiments, equal
amounts of PBMCs were used, and the amount of sIL-6R in the supernatant of the
PBMCs quantiﬁed with an ELISA speciﬁc for the IL-6R. Cells were stimulated as follows:
A. 1 μM ionomycin (1 h), B. 100 nM PMA (2 h), C. 1 μM ionomycin plus either 3 μM GI
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inhibitors 30 min before addition of either PMA or ionomycin. P-values of the statistical
analysis are given above the respective ﬁgure.
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324 was blocked by GI and GW or only GW, respectively (Fig. 3E and F).
325 These results conﬁrmed that ionomycin-induced ADAM10-mediated
326 IL-6R shedding, whereas PMA selectively activated ADAM17 and that
327 both proteases contribute to increased shedding of the Asp358Ala
328 IL-6R variant.
329 3.4. ADAM10 and ADAM17 are responsible for increased proteolysis of the
330 Asp358Ala IL-6R variant
331 Next, we used murine embryonic ﬁbroblasts (MEFs) deﬁcient for
332 either ADAM10, ADAM17, or both proteases [7], to further analyze
333 shedding of the Asp358Ala IL-6R variant. Overall cellular expression
334 of the common and the Asp358Ala IL-6R variant wasQ4 comparable or, if
335at all, minimally reduced for the Asp358Ala IL-6R in all MEFs tested
336(Fig. 4A). If the increased shedding of the IL-6R Asp358Ala IL-6R variant
337would be due to an increased protein biosynthesis than increased IL-6R
338expression of the Asp358Ala IL-6R variant would have been expected.
339Again constitutive and ionomycin- or PMA-induced shedding of the
340Asp358Ala IL-6R variant was slightly increased compared to the com-
341mon IL-6R variant (Fig. 4B). ADAM10 deﬁcient MEFs also released
342more sIL-6R after ionomycin- and PMA-stimulation (Fig. 4C). Although
343ADAM10 is lacking in these cells, we observed ionomycin-induced
344IL-6R shedding. As reported previously, compensatory shedding of
345human IL-6R was mediated by ADAM17 after ionomycin stimulation
346in ADAM10-deﬁcient murine embryonic ﬁbroblasts [7]. This phenome-
347non has also been described for other ADAM10/17 substrates [34]. As
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348 expected, IL-6R shedding in ADAM17 deﬁcient MEFs was not induced
349 after PMA-treatment, since PMA solely activates ADAM17, which can-
350 not be compensated by ADAM10. Ionomycin-induced shedding led to
351 slightly more shed IL-6R in case of the Asp358Ala variant as compared
352 to the common variant (Fig. 4D). In MEFs deﬁcient for both ADAM10
353 and ADAM17 constitutive and PMA- and ionomycin-induced shedding
354 IL-6R shedding was completely abrogated for both IL-6R variants
355 (Fig. 4E). From these experiments we concluded that increased shed-
356 ding of the Asp358Ala IL-6R variant was mediated by ADAM10 and
357 ADAM17.
358 3.5. The Asp358Ala IL-6R variant has an increased inducible shedding
359 susceptibility on PBMCs
360 To conﬁrm our data in primary cells, we analyzed ectodomain shed-
361 ding of the IL-6R Asp358Ala variant on human PBMCs. Unstimulated
362 PBMCs from healthy volunteers had already shown a signiﬁcantly in-
363 creased sIL-6R release (2.5 ± 1.1-fold, p = 0.025) from PBMCs homo-
364 zygous for the Asp358Ala IL-6R variant (Fig. 1F). Thus, PBMCs were
365 used again from the ten volunteers, homozygous either for the common
366 or the IL-6R Asp358Ala allele. PBMCs were either stimulated with
367 ionomycin, PMA or left untreated to analyze induced IL-6R ectodomain
368 shedding. Stimulation with ionomycin or PMA strongly induced IL-6R
369 proteolysis of both IL-6 variants, shedding of the Asp358Ala IL-6R
370 variant was 1.8 ± 0.6 (p = 0.016) and 1.9 ± 0.3-fold (p = 0.075)
371 increased compared to common IL-6R variant, respectively (Fig. 5A, B).
372 Ionomycin and PMA-induced shedding was signiﬁcantly suppressed
373 by co-incubation with GI and GW or GW alone, respectively
374 (Fig. 5C, D), indicating that the sIL-6R was generated by ADAM10-
375 and ADAM17-mediated ectodomain shedding and not by differential
376 splicing.
377 3.6. Overexpression of protein kinase C strongly enhanced ADAM17-
378 mediated IL-6R shedding and abolished the differential shedding of the
379 IL-6R variants
380 PMA-induced ADAM17-mediated shedding of the IL6R is dependent
381 on activation of the protein kinase C (PKCα) [35]. Co-transfection of
382 cDNAs coding for PKCα and the common IL-6R variant led to massively
383 increased constitutive and PMA-induced IL-6R shedding as compared to
384 IL-6R transfected HEK293 cells (p b 0.05, Fig. 6A), demonstrating that
385 the endogenous PKCα level is rate limiting for IL-6R shedding, which
386 was boosted by PKCα co-expression. Interestingly, co-expression of
387 IL-6R and PKCα abolished differences between the shedding of the com-
388 mon and the Asp358Ala IL-6R variant (Fig. 6A). Inhibition of ADAM17-
389 mediated shedding by GW reduced PMA-induced shedding, but
390 not below the level of constitutive shedding (Fig. 6A), suggesting that
391 PKCαmight induce a so-far not-identiﬁed IL-6R sheddase. It is, howev-
392 er, not known if this unknown protease is also responsible for constitu-
393 tive shedding under non-PKCα-overexpressing conditions.
394 We veriﬁed these ﬁndings via ﬂow cytometry. Whereas we ob-
395 served only a very small reduction of cell-surface IL-6Rwhenwe stimu-
396 lated HEK293 cells transfected with wildtype IL-6R (Fig. 6B), the cell-
397 surface reduction of the Asp358Ala variant was more pronounced
398 after PMA stimulation (Fig. 6C), thus reﬂecting the ELISAmeasurements
399 (Fig. 6A). Interestingly, the majority of the IL-6R appeared to be still
400 present on the cell surface. This suggests that the endogenous level of
401 PKCα in HEK293 cells is not sufﬁcient to induce full-blown ADAM17-
402 mediated IL-6R shedding. In sharp contrast, PKC overexpression led to
403 an increased cell-surface loss of both IL-6R variants (Fig. 6D and E),
404 thereby conﬁrming the results obtained via ELISA measurement
405 (Fig. 6A). PKCα overexpression seemed not only to even the differences
406 between the common and the Asp358Ala variant of the IL-6R, but also
407 to lead to a preferential cleavage of the common variant (Fig. 6A,
408 D, E). The reason behind this is currently unknown andwarrants further
409 investigation.
4104. Discussion
411Here, we provide evidence that the IL-6R SNP rs2228145 leads to
412increased constitutive and induced ectodomain shedding of the IL-6R
413by ADAM proteases. Overall steady state cell surface expression of
414Asp358Ala IL-6R variant is reduced compared to the common IL-6R
415variant. Paradoxically, despite reduced cell surface IL-6R expression,
416inducing ectodomain shedding by ionomycin or PMA still resulted in
417increased sIL-6R generation of the Asp358Ala IL-6R variant compared
418to the common IL-6R variant. This effect might be explained by incom-
419plete PMA- and ionomycin-induced shedding of the IL-6R, which is not
420sufﬁcient to release all cell surface IL-6R molecules. This notion is sup-
421ported by our PKC co-expression experiments. Forcing ectodomain
422shedding of the IL-6R by over-expression of PKCα revealed the full po-
423tential of IL-6R ectodomain shedding. Even though PMA is the strongest
424inducer of IL-6R shedding described to date, co-expression of PKCα
425result in 3–4-fold increase of PMA-induced IL-6R shedding revealing
426the full potential of ADAM-mediated IL-6R shedding. Interestingly,
427under these conditions no differences in PMA-induced shedding of the
428common and the Asp358Ala IL-6R variants were observed.
429Limited proteolysis of transmembrane proteins occurs usually in
430close proximity to the plasmamembrane, and the shedding susceptibil-
431ity of this Q5is critically inﬂuenced by the amino acids surrounding the
432cleavage sites. ADAM17 cleaves the IL-6R between Gln357 and Asp358
433within the so-called stalk region [16], which consists of 52 amino
434acids [17]. The stalk region is considered to function as a spacer to posi-
435tion the three extracellular domains of the IL-6R towards gp130. Until
436now, no structural data of the stalk region are available [36,37], but
437overall the stalk is considered to lack a domain structure. Interestingly,
438other non-naturally occurring pointmutationswithin the IL-6R resulted
439in reduced shedding of the IL-6R [16]. Also small deletions within the
440stalk region reduced IL-6R shedding [17]. To date, no consensus se-
441quence for ADAM10 or ADAM17 cleavage sites has been identiﬁed.
442However, our data show that ADAM17 might favor the cleavage after
443a small, non-charged amino acid like alanine instead of aspartic acid.
444IL-6 is found in the blood at 1–5 pg/ml but increases to ng/ml con-
445centrations during pathophysiology [1]. The serum concentration of
446the sIL-6R is about 20 ng/ml and of sgp130 is about 100–200 ng/ml
447[1]. The IL-6R SNP rs2228145 leads to a doubling of sIL-6R level in the
448blood [10,11], and this has been shown to be associated with reduced
449CRP level [8,9]. Two different mechanisms might be responsible for
450this, ormay act in concert. Circulating IL-6will bind to sIL-6R and subse-
451quently to sgp130, which is the natural inhibitor of the IL-6 trans-
452signaling [1]. Thus, sIL-6R and sgp130 in the serum can act to buffer sys-
453temic activities of IL-6. Since sgp130 is available in excess, a doubling of
454sIL-6R would indeed increase this buffer capacity. However, thus far no
455experiments were conducted to proof this hypothesis. An increased
456proteolytic conversion of IL-6R due to the Asp358Ala SNP might there-
457fore contribute to this increased buffer capacity of IL-6 and to overall re-
458duced IL-6 activity [5,38]. Furthermore, the reduced membrane-bound
459IL-6R on hepatocytes of humans homozygous for the rs2228145 SNP
460might lead to reduced IL-6 classic-signaling and subsequently to
461reduced CRP production [15,39].
462Taken together, our data strongly suggested that ectodomain
463shedding but not alternative splicing mainly contributes to the reduced
464cell surface IL-6R levels and increased sIL-6R serum levels found in indi-
465viduals homozygous for the IL-6R rs2228145 SNP.
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